11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

KDIGO Staging & Diagnosis of Acute Kidney Injury

Acute Kidney Injury (AKI) represents an abrupt decline in glomerular filtration rate (GFR) resulting in the accumulation of nitrogenous waste products (urea, creatinine) and loss of fluid and electrolyte homeostasis. The Kidney Disease: Improving Global Outcomes (KDIGO) consensus criteria standardize AKI definition and staging based on serum creatinine changes and oliguria duration:

Clinical Limitations of Serum Creatinine in Emergency Care

Serum creatinine is a delayed surrogate marker of renal function. Following an acute ischemic or nephrotoxic insult, serum creatinine accumulation lags 24 to 48 hours behind the true drop in GFR. Furthermore, serum creatinine is confounded by muscle mass, age, baseline protein intake, and intravascular volume overload (where aggressive crystalloid resuscitation hemodilutes creatinine, masking significant AKI).

---

Contrast-Associated AKI (CA-AKI) Prevention

Contrast-Associated Acute Kidney Injury (CA-AKI)—historically termed contrast-induced nephropathy (CIN)—is defined as an absolute increase in serum creatinine $\ge 0.3\text{ mg/dL}$ or a relative increase $\ge 50\%$ over baseline occurring within 48 to 72 hours following intravascular administration of iodinated radiocontrast media.

Pathophysiological Mechanisms

1. Renal Medullary Hypoxia: Radiocontrast media triggers intense, prolonged vasoconstriction of the renal descending vasa recta, mediated by endothelin, adenosine, and reactive oxygen species, collapsing oxygen delivery to the metabolically active medullary thick ascending limb of Henle.
2. Direct Tubular Cytotoxicity: Filtered hyperosmolar contrast is concentrated in tubular fluid, directly damaging proximal tubular epithelial cells via oxidative stress, mitochondrial fragmentation, and apoptosis.

                  CA-AKI PREVENTION: EVIDENCE VS MYTHS
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ PROVEN EFFECTIVE: INTRAVENOUS VOLUME EXPANSION                              │
  │   • Isotonic Crystalloids (0.9% NaCl or Balanced Crystalloid)               │
  │   • Regimen: 1.0–1.5 mL/kg/h for 3–12h pre- and 6–12h post-contrast         │
  │   • Urgent ED Regimen: 3 mL/kg IV over 1 hour pre-contrast                  │
  │   • Mechanism: Expands intravascular volume, suppresses renin-angiotensin-  │
  │     aldosterone axis, dilutes contrast in tubular lumen, accelerates flow   │
  ├─────────────────────────────────────────────────────────────────────────────┤
  │ INEFFECTIVE / NOT RECOMMENDED (PRESERVE TRIAL 2018):                        │
  │   • N-Acetylcysteine (NAC): No benefit over isotonic saline                 │
  │   • Sodium Bicarbonate Infusion: No superiority over isotonic saline        │
  │   • Prophylactic Hemodialysis: Fails to prevent CA-AKI; may worsen outcomes │
  └─────────────────────────────────────────────────────────────────────────────┘

---

Physicochemical Determinants of Extracorporeal Drug Dialyzability

When evaluating whether a drug is cleared by intermittent hemodialysis (IHD) or continuous renal replacement therapy (CRRT: CVVH, CVVHD, CVVHDF), emergency medicine specialists must assess four fundamental physicochemical and pharmacokinetic properties:

                     DETERMINANTS OF DRUG DIALYZABILITY
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ 1. MOLECULAR WEIGHT (MW)                                                    │
  │    • Low-flux IHD filter cutoff: ~500–1,000 Daltons                         │
  │    • High-flux IHD & CRRT membrane pore cutoff: ~20,000–30,000 Daltons      │
  │    • Small molecules (<500 Da) easily cleared; large molecules trapped      │
  ├─────────────────────────────────────────────────────────────────────────────┤
  │ 2. PROTEIN BINDING (UNBOUND FRACTION, fu)                                   │
  │    • Only the free, unbound drug fraction passes through membrane pores     │
  │    • Drugs with >80%–90% protein binding (e.g., ceftriaxone) NOT dialyzable │
  ├─────────────────────────────────────────────────────────────────────────────┤
  │ 3. VOLUME OF DISTRIBUTION (Vd)                                              │
  │    • Low Vd (<0.7 L/kg): Drug confined to plasma water ──> High Dialyzability│
  │    • High Vd (>1–2 L/kg): Drug sequestered in deep tissues ──> NOT Dialyzable│
  │      (Post-dialysis plasma concentration rebound occurs)                    │
  ├─────────────────────────────────────────────────────────────────────────────┤
  │ 4. WATER SOLUBILITY VS LIPOPHILICITY                                        │
  │    • Hydrophilic drugs partition into dialysate/filtrate water              │
  │    • Lipophilic drugs distribute into cellular membranes and adipose tissue │
  └─────────────────────────────────────────────────────────────────────────────┘

Dialysis Clearance Matrix for High-Yield Emergency Medications

---

CRRT vs IHD Drug Dosing Principles in Sepsis

Continuous Renal Replacement Therapy (CRRT)—administered as Continuous Veno-Venous Hemofiltration (CVVH, convective), Continuous Veno-Venous Hemodialysis (CVVHD, diffusive), or Continuous Veno-Venous Hemodiafiltration (CVVHDF, combined)—is preferred in hemodynamically unstable critically ill patients because continuous fluid and solute removal avoids the precipitous hypotension seen with intermittent hemodialysis.

The "Septic Shock Under-Dosing" Crisis in CRRT

In critically ill septic shock patients undergoing CRRT, two concurrent physiological forces dramatically alter drug kinetics:

1. Massively Expanded Volume of Distribution: Capillary endothelial leak and aggressive crystalloid volume resuscitation expand the extracellular fluid space, diluting hydrophilic antibiotics (beta-lactams, aminoglycosides, glycopeptides).
2. High Continuous Extracorporeal Clearance: Recommended CRRT effluent flow rates of 20 to 25 mL/kg/h clear hydrophilic drugs at roughly the rate of a native GFR of 25 to 35 mL/min (a 25 mL/kg/h effluent in a 70 kg adult is about 29 mL/min).

Golden Rules of RRT Resuscitation Antimicrobial Dosing

• Rule 1: Always Administer a Full, Unadjusted Loading Dose:
  • Initial drug distribution depends strictly on the volume of distribution ($V_d$), NOT on renal clearance or dialysis modality.
  • Administer full weight-based loading doses immediately in the ED: Vancomycin 25 to 30 mg/kg, Cefepime 2 g IV, Meropenem 2 g IV, Piperacillin-Tazobactam 4.5 g IV.
• Rule 2: Dose CRRT Maintenance by Effluent Rate:
  • At standard effluent flow rates ($20\text{ to }25\text{ mL/kg/h}$), maintenance dosing should approximate moderate renal impairment (GFR roughly 25–50 mL/min). For example, use Cefepime 2 g IV every 12 hours (or 1 g IV every 8 hours) or Meropenem 1 g IV every 8 hours via extended infusions (over 3 hours) to optimize time-dependent pharmacodynamics ($fT > \text{MIC}$). Adjust down only if effluent flow is interrupted or reduced.

---

Emergency Department Nephrotoxic Stewardship

Medication stewardship in the emergency department focuses on early identification of drug-induced nephrotoxic combinations, individualized dosing adjustments, and proactive laboratory monitoring.

The "Triple Whammy" Renal Collapse

The concurrent administration of an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) + Loop Diuretic + Nonsteroidal Anti-inflammatory Drug (NSAID) creates a hemodynamic collapse of intraglomerular filtration pressure.

                  THE "TRIPLE WHAMMY" HEMODYNAMIC COLLAPSE
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ 1. LOOP DIURETIC (Furosemide):                                              │
  │    --> Promotes systemic intravascular volume depletion                     │
  │    --> Reduces renal plasma inflow and baseline perfusion                   │
  ├─────────────────────────────────────────────────────────────────────────────┤
  │ 2. NSAID (Ketorolac / Ibuprofen):                                           │
  │    --> Blocks COX-1 and COX-2 synthesis of prostaglandins (PGE2, PGI2)      │
  │    --> Constricts the AFFERENT arteriole (impedes glomerular blood inflow)  │
  ├─────────────────────────────────────────────────────────────────────────────┤
  │ 3. ACE INHIBITOR / ARB (Lisinopril / Losartan):                             │
  │    --> Inhibits Angiotensin II-mediated vasoconstriction                    │
  │    --> Dilates the EFFERENT arteriole (allows unrestricted blood outflow)   │
  ├─────────────────────────────────────────────────────────────────────────────┤
  │ RESULT: Glomerular capillary hydrostatic pressure plummets ──> Acute AKI    │
  └─────────────────────────────────────────────────────────────────────────────┘

• Clinical Action in ED: Avoid prescribing parenteral or oral NSAIDs (such as ketorolac) in elderly patients or those taking baseline ACEI/ARBs and diuretics. Utilize multimodal non-nephrotoxic analgesics (acetaminophen, topical lidocaine, regional nerve blocks, or low-dose opioids).

Single-Daily Extended-Interval Aminoglycoside Dosing

Aminoglycosides (gentamicin, tobramycin, amikacin) exhibit concentration-dependent bacterial killing (optimal $C_{\max}/\text{MIC} \ge 8\text{ to }10$) coupled with saturable receptor-mediated endocytosis into renal proximal tubular cells via the megalin/cubilin receptor complex.

• Pharmacokinetic Rationale: Administering a large single daily dose (5 to 7 mg/kg of gentamicin/tobramycin) saturates proximal tubular uptake while producing high peak concentrations. As serum concentrations decline over the 24-hour dosing interval to undetectable levels ($< 0.5\text{ to }1.0\text{ mcg/mL}$), intracellular aminoglycosides are slowly cleared out of tubular lysosomes back into urine, minimizing cortical drug accumulation and dramatically reducing nephrotoxicity compared to traditional multiple daily dosing (1.5 to 2 mg/kg q8h).

Vancomycin AUC24/MIC Stewardship vs Trough Targets

The updated 2020 consensus guidelines by ASHP/IDSA/PIDS/SIDP recommend against targeting elevated vancomycin trough concentrations of 15 to 20 mcg/mL for serious MRSA infections.

• The AUC Paradigm: Vancomycin antibacterial efficacy is driven by the 24-hour area under the concentration-time curve to minimum inhibitory concentration ratio: $\text{AUC}_{24}/\text{MIC} = 400\text{ to }600\text{ mg}\cdot\text{h/L}$
• Safety Superiority: Targeting trough levels of 15 to 20 mcg/mL frequently produces supratherapeutic AUCs ($>650\text{ to }800\text{ mg}\cdot\text{h/L}$), increasing acute kidney injury rates three- to four-fold without enhancing microbiological clearance. AUC-guided dosing—derived using Bayesian modeling or two post-distribution concentrations (peak at 1–2h post-infusion and trough at 30 min pre-dose)—reduces nephrotoxicity while maintaining therapeutic cure rates.